BACKGROUND: The National Lung Screening Trial (NLST), which was conducted between 2002 and 2009, demonstrated that screening with low-dose computed tomography (LDCT) reduced lung cancer mortality by 20% among screening-eligible populations compared with chest x-ray. In this article, the authors provide an estimate of the annual number of lung cancer deaths that can be averted by screening, assuming the screening regimens adopted in the NLST are fully implemented in the United States. METHODS: The annual number of lung cancer deaths that can be averted by screening was estimated as a product of the screening effect, the US population size (obtained from the 2010 US Census data), the prevalence of screening eligibility (estimated using the 2010 National Health Interview Survey [NHIS] data), and the lung cancer mortality rates among screening-eligible populations (estimated using the NHIS data from 2000-2004 and the third National Health and Nutrition Examination Survey linked mortality files). Analyses were performed separately by sex, age, and smoking status, with Poisson regression analysis used for mortality rate estimation. Uncertainty of the estimates of the number of avertable lung cancer deaths was quantified by simulation. RESULTS: Approximately 8.6 million Americans (95% confidence interval [95% CI], 8.0 million-9.2 million), including 5.2 million men (95% CI, 4.8 million-5.7 million) and 3.4 million women (95% CI, 3.0 million -3.8 million), were eligible for lung cancer screening in 2010. If the screening regimen adopted in the NLST was fully implemented among these screening-eligible US populations, a total of 12,250 (95% CI, 10,170-15,671) lung cancer deaths (8990 deaths in men and 3260 deaths in women) would be averted each year. CONCLUSIONS: The data from the current study indicate that LDCT screening could potentially avert approximately 12,000 lung cancer deaths per year in the United States. Further studies are needed to estimate the number of avertable lung cancer deaths and the cost-effectiveness of LDCT screening under different scenarios of risk, various screening frequencies, and various screening uptake rates.
BACKGROUND: The National Lung Screening Trial (NLST), which was conducted between 2002 and 2009, demonstrated that screening with low-dose computed tomography (LDCT) reduced lung cancer mortality by 20% among screening-eligible populations compared with chest x-ray. In this article, the authors provide an estimate of the annual number of lung cancer deaths that can be averted by screening, assuming the screening regimens adopted in the NLST are fully implemented in the United States. METHODS: The annual number of lung cancer deaths that can be averted by screening was estimated as a product of the screening effect, the US population size (obtained from the 2010 US Census data), the prevalence of screening eligibility (estimated using the 2010 National Health Interview Survey [NHIS] data), and the lung cancer mortality rates among screening-eligible populations (estimated using the NHIS data from 2000-2004 and the third National Health and Nutrition Examination Survey linked mortality files). Analyses were performed separately by sex, age, and smoking status, with Poisson regression analysis used for mortality rate estimation. Uncertainty of the estimates of the number of avertable lung cancer deaths was quantified by simulation. RESULTS: Approximately 8.6 million Americans (95% confidence interval [95% CI], 8.0 million-9.2 million), including 5.2 million men (95% CI, 4.8 million-5.7 million) and 3.4 million women (95% CI, 3.0 million -3.8 million), were eligible for lung cancer screening in 2010. If the screening regimen adopted in the NLST was fully implemented among these screening-eligible US populations, a total of 12,250 (95% CI, 10,170-15,671) lung cancer deaths (8990 deaths in men and 3260 deaths in women) would be averted each year. CONCLUSIONS: The data from the current study indicate that LDCT screening could potentially avert approximately 12,000 lung cancer deaths per year in the United States. Further studies are needed to estimate the number of avertable lung cancer deaths and the cost-effectiveness of LDCT screening under different scenarios of risk, various screening frequencies, and various screening uptake rates.
Authors: Cherie P Erkmen; Mark Mitchell; Simran Randhawa; Shelby Sferra; Rachel Kim; Verdi DiSesa; Larry R Kaiser; Grace X Ma Journal: J Community Health Date: 2018-02
Authors: Lisa M Fucito; Sharon Czabafy; Peter S Hendricks; Chris Kotsen; Donna Richardson; Benjamin A Toll Journal: Cancer Date: 2016-02-24 Impact factor: 6.860
Authors: Lonny B Yarmus; Sixto Arias; David Feller-Kopman; Roy Semaan; Ko Pen Wang; Bernice Frimpong; Karen Oakjones Burgess; Richard Thompson; Alex Chen; Ricardo Ortiz; Hans J Lee Journal: J Thorac Dis Date: 2016-01 Impact factor: 2.895
Authors: Kathryn L Taylor; Charlotte J Hagerman; George Luta; Paula G Bellini; Cassandra Stanton; David B Abrams; Jenna A Kramer; Eric Anderson; Shawn Regis; Andrea McKee; Brady McKee; Ray Niaura; Harry Harper; Michael Ramsaier Journal: Lung Cancer Date: 2017-02-15 Impact factor: 5.705
Authors: Kathryn L Taylor; Danielle E Deros; Shelby Fallon; Jennifer Stephens; Emily Kim; Tania Lobo; Kimberly M Davis; George Luta; Jinani Jayasekera; Rafael Meza; Cassandra A Stanton; Raymond S Niaura; David B Abrams; Brady McKee; Judith Howell; Michael Ramsaier; Juan Batlle; Ellen Dornelas; Vicky Parikh; Eric Anderson Journal: Contemp Clin Trials Date: 2019-05-23 Impact factor: 2.226
Authors: Amelia W Maiga; Stephen A Deppen; Sarah Fletcher Mercaldo; Jeffrey D Blume; Chandler Montgomery; Laszlo T Vaszar; Christina Williamson; James M Isbell; Otis B Rickman; Rhonda Pinkerman; Eric S Lambright; Jonathan C Nesbitt; Eric L Grogan Journal: JAMA Surg Date: 2018-04-01 Impact factor: 14.766